Prospector
Profile
07.1381
|
| |
| Brainstorm Cell Therapeutics, Inc. |
NAICS |
541710 |
| 110 East 59th Street
New York, NY 10022 |
Description |
Biotechnology |
| (212) 557-9000 |
Employees |
12 |
| http://www.brainstorm-cell.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-3.3160 |
| |
Assets |
(mil) |
0.8590 |
| |
Liability |
(mil) |
8.7700 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Kost Forer Gabbay & Kasierer states that Brainstorm Cell Therapeutics, Inc. has incurred operating losses and has a negative cash flow from operating activities and has a working capital deficiency. In addition, the Company is in breach of its research and development license agreement with Ramot. These conditions raise substantial doubt about the Company's ability to continue as a going concern.
|
| |
|
Intellectual Property:
The Company has filed three patent applications for its NurOwn™ technology (PCT/IL03/00972; PCT/IL2006/000699 and PCT/IL/2006/000140). It has also filed an application for the trademark NurOwn™. The Company holds exclusive worldwide rights to commercialize the NurOwn™ technology, through a licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. [SEC Filing 10-KSB 03-30-07]
|
| |
|
Description:
The Company develops stem cell therapeutic products based on technologies enabling the in vitro differentiation of bone marrow stem cells to neural-like cells.
|
| |
|
Officers:
Yoram Drucker (CEO & COO); David Stolick (CFO); Irit Arbel (Dir.); Michael Greenfield (Dir.); Robert Shorr (Dir.)
|
| |
|
Auditor:
Kost Forer Gabbay & Kasierer
|
| |
|
Securities:
Common Stock-Symbol BCLI.OB; OTC BB;
common shares outstanding as of August 17, 2007.
|
| |
| |
| |
| return to main page |
